Early Data Shows Novavax's COVID-19 Vaccine Triggers Immune Response To Omicron


Novavax Inc NVAX said its two-dose COVID-19 vaccine effectively generates an immune response against the Omicron variant, according to early data.

  • Though the company said neutralization against the Omicron variant was "4-fold lower" than it was against the original strain of the virus, suggesting that a booster shot or a new Omicron-specific vaccine would be beneficial.
  • A third shot six months after the first two doses indicated an increase in antibodies to levels associated with protection seen in earlier large clinical trials.
  • Related Link: Novavax Reports Initiation Of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study.
  • "We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials, suggesting that NVX-CoV2373 can play an important role in the ongoing fight against new variants," said Gregory Glenn, President of Research and Development, Novavax.
  • Further, data from the pediatric expansion of Novavax's PREVENT-19 Phase 3 trial showed robust immune responses in adolescents, against a wide array of variants, including Omicron, following a 2-dose series. 
  • Responses in adolescents were 2- to 4-fold higher than adults against all evaluated variants.
  • Novavax is developing an omicron-specific vaccine and expects to begin manufacturing doses of the variant-specific shot in January.
  • Price Action: NVAX shares are up 5.81% at $193.95 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLong IdeasNewsHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 VaccinePhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!